199 related articles for article (PubMed ID: 16269991)
1. [New treatment strategies for type-2 diabetes?].
Halimi S
Presse Med; 2005 Oct; 34(18):1287-92. PubMed ID: 16269991
[TBL] [Abstract][Full Text] [Related]
2. Optimizing diabetes care regarding cardiovascular targets at general practice level: Direct@GP.
Wens J; Gerard R; Vandenberghe H
Prim Care Diabetes; 2011 Apr; 5(1):19-24. PubMed ID: 21030327
[TBL] [Abstract][Full Text] [Related]
3. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis.
Jialal I; Abby SL; Misir S; Nagendran S
Metab Syndr Relat Disord; 2009 Jun; 7(3):255-8. PubMed ID: 19344229
[TBL] [Abstract][Full Text] [Related]
4. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices.
Corcillo A; Pivin E; Lalubin F; Pitteloud N; Burnier M; Zanchi A
Swiss Med Wkly; 2017; 147():w14459. PubMed ID: 28695552
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
6. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
7. Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE.
Gitt AK; Schmieder RE; Duetting E; Bramlage P; Schneider S; Tschöpe D;
Cardiovasc Diabetol; 2012 Dec; 11():148. PubMed ID: 23216660
[TBL] [Abstract][Full Text] [Related]
8. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk management in type 2 diabetes of more than 10-year duration: Results of Polish ARETAEUS2-Grupa Study.
Leśniak W; Bała MM; Płaczkiewicz-Jankowska E; Topór-Mądry R; Jankowski M; Sieradzki J; Banasiak W;
Cardiol J; 2015; 22(2):150-9. PubMed ID: 25299503
[TBL] [Abstract][Full Text] [Related]
10. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
11. Glycaemic, blood pressure and cholesterol control in 25 629 diabetics.
Pinchevsky Y; Butkow N; Chirwa T; Raal FJ
Cardiovasc J Afr; 2015; 26(4):188-92. PubMed ID: 26407221
[TBL] [Abstract][Full Text] [Related]
12. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
Boytsov S; Logunova N; Khomitskaya Y;
Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
[TBL] [Abstract][Full Text] [Related]
13. [Type 2 diabetes: what therapeutic strategy?].
Grimaldi A; Hartemann-Heurtier A
Presse Med; 2001 Feb; 30(6):288-97. PubMed ID: 11252980
[TBL] [Abstract][Full Text] [Related]
14. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology.
Gyberg V; De Bacquer D; De Backer G; Jennings C; Kotseva K; Mellbin L; Schnell O; Tuomilehto J; Wood D; Rydén L; Amouyel P; Bruthans J; Conde AC; Cifkova R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pająk A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D;
Cardiovasc Diabetol; 2015 Oct; 14():133. PubMed ID: 26427624
[TBL] [Abstract][Full Text] [Related]
15. Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey.
Grenier J; Goodman SG; Leiter LA; Langer A; Teoh H; Bhatt DL; Cheng AYY; Tan MK; Ransom T; Connelly KA; Yan AT
Can J Diabetes; 2018 Apr; 42(2):130-137. PubMed ID: 28552652
[TBL] [Abstract][Full Text] [Related]
16. [Quality of the treatment of type 2 diabetes: results from the GIANTT project 2004-2007].
Voorham J; Haaijer-Ruskamp FM; van der Meer K; de Zeeuw D; Wolffenbuttel BH; Hoogenberg K; Denig P
Ned Tijdschr Geneeskd; 2010; 154():A775. PubMed ID: 20132579
[TBL] [Abstract][Full Text] [Related]
17. Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to aNalyse Type 2 diabetes Treatment (GIANTT) observational study.
Voorham J; Haaijer-Ruskamp FM; van der Meer K; de Zeeuw D; Wolffenbuttel BH; Hoogenberg K; Denig P;
Pharmacoepidemiol Drug Saf; 2010 Oct; 19(10):1078-86. PubMed ID: 20687048
[TBL] [Abstract][Full Text] [Related]
18. [Management of type 2 diabetes: new or previous agents, how to choose?].
Halimi S
Presse Med; 2013 May; 42(5):861-70. PubMed ID: 23643613
[TBL] [Abstract][Full Text] [Related]
19. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.
Reboldi G; Gentile G; Angeli F; Verdecchia P
Vasc Health Risk Manag; 2009; 5(1):411-27. PubMed ID: 19475778
[TBL] [Abstract][Full Text] [Related]
20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
